Codexis and Axolabs Sign Agreement to Evaluate ECO Synthesis Manufacturing Platform
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2026
0mins
Should l Buy CDXS?
Codexis and Axolabs, part of LGC Group, an oligonucleotide Contract Research Development and Manufacturing organization, announced that they have entered into an agreement under which Axolabs will evaluate Codexis' ECO Synthesis Manufacturing Platform. This partnership provides Axolabs access to an innovative, scalable RNA manufacturing solution powered by enzymatic synthesis. The Agreement paves the way for future licensing discussions and potentially broader adoption of the platform.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CDXS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CDXS
Wall Street analysts forecast CDXS stock price to rise
5 Analyst Rating
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 1.240
Low
2.00
Averages
6.00
High
11.00
Current: 1.240
Low
2.00
Averages
6.00
High
11.00
No data
About CDXS
Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Codexis Reports 2025 Earnings, Significant Progress on ECOsynthesis Platform
- Market Potential: Codexis anticipates a $2 billion addressable market for production technologies in five years, driven by a 5% to 10% annual growth in siRNA drug development, positioning the company as a key technology provider in this space.
- Technical Milestone: In 2025, Codexis successfully synthesized 10 grams of commercially relevant siRNA, demonstrating the production capabilities of its ECOsynthesis platform without quality barriers, marking a significant advancement in biocatalytic enzyme innovation.
- Production Capacity Expansion: In 2026, Codexis has scaled production to 100 grams at its Eco Innovation Lab, with plans to reach half a kilo by year-end, further addressing customer demand for large-scale siRNA production.
- Strong Financial Performance: Codexis reported total revenues of $38.9 million for 2025, a significant increase from $21.5 million in 2024, primarily driven by a technology transfer agreement with Merck, with 2026 revenue expected to range between $72 million and $76 million.
See More
Codexis Reports Significant Growth in FY 2025 Performance
- Significant Revenue Growth: Codexis achieved total revenue of $70.4 million in FY 2025, a 19.1% increase from $59.3 million in FY 2024, indicating strong performance amid recovering market demand, which is expected to further boost investor confidence.
- Improved Gross Margin: The product gross margin for FY 2025 reached 64%, up from 56% in FY 2024, reflecting successful cost control and pricing strategies that enhance profitability and operational efficiency.
- R&D Spending Adjustments: Although R&D expenses increased to $52.3 million for FY 2025, Q4 spending was $11.7 million, down from $12.1 million in Q4 2024, demonstrating the company's flexible adjustments in R&D investment to respond to market dynamics.
- Strong Cash Position: By the end of 2025, Codexis reported $78.2 million in cash and short-term investments, bolstered by a $37.8 million technology transfer agreement with Merck, ensuring operational and capital expenditure needs for the next two years, thereby enhancing financial stability.
See More
Codexis Q4 2025 Earnings Call Highlights
- Significant Revenue Growth: Codexis reported total revenues of $38.9 million for Q4 2025, an 80% increase from $21.5 million in Q4 2024, primarily driven by a technology transfer agreement with Merck, indicating strong market demand in the RNA medicine sector.
- Technical Milestone Achieved: The company successfully synthesized 10 grams of commercially relevant siRNA, marking a significant technical advancement for the ECO Synthesis production platform, with plans to scale up to 0.5 kilograms by year-end, further solidifying its market position in chemoenzymatic production.
- Production Capacity Expansion: Codexis is set to complete the construction of a new GMP facility by the end of 2027, which is expected to significantly enhance its production capabilities to meet growing customer demands, bolstered by three CDMO agreements signed with Bachem, Nitto Avecia, and Axolabs.
- Improved Financial Position: Although the net loss for 2025 was $44 million, an improvement from a $65.3 million loss in 2024, the company achieved a net income of $9.6 million in Q4, reflecting a positive shift towards profitability and operational efficiency.
See More
Codexis (CDXS) Q4 2025 Earnings Call Transcript
See More
Codexis Q4 Earnings Exceed Expectations
- Strong Performance: Codexis reported a Q4 GAAP EPS of $0.11, beating expectations by $0.14, indicating a significant improvement in profitability and enhancing its competitive position in the market.
- Revenue Surge: The company achieved Q4 revenue of $38.9 million, representing an 81.3% year-over-year increase and exceeding market expectations by $3.07 million, highlighting Codexis's robust business expansion and demand.
- Positive Outlook: Total revenues are projected to range between $72 million and $76 million for 2026, providing investor confidence and indicating the company's potential for sustained growth in the coming years.
- Sufficient Funding: Codexis expects that its existing cash, cash equivalents, and short-term investments will be adequate to fund planned operations through the end of 2027, demonstrating sound financial management and sustainability.
See More
Codexis to Announce Q4 Earnings on March 11
- Earnings Announcement Schedule: Codexis is set to release its Q4 earnings on March 11 after market close, with market participants keenly awaiting the results, which are expected to influence stock performance.
- EPS Expectations: Analysts forecast an EPS of -$0.04, representing a 69.2% year-over-year improvement, indicating significant potential for enhanced profitability for the company.
- Revenue Growth Forecast: The revenue estimate stands at $35.83 million, reflecting a 67.0% year-over-year increase, showcasing strong market demand and sales growth that could bolster investor confidence.
- Historical Performance Insight: Historical financial data indicates that Codexis has shown gradual improvement over recent quarters, and if this earnings report meets expectations, it will further solidify its market position in the biotechnology sector.
See More
Codexis Reports 2025 Earnings, Significant Progress on ECOsynthesis Platform
- Market Potential: Codexis anticipates a $2 billion addressable market for production technologies in five years, driven by a 5% to 10% annual growth in siRNA drug development, positioning the company as a key technology provider in this space.
- Technical Milestone: In 2025, Codexis successfully synthesized 10 grams of commercially relevant siRNA, demonstrating the production capabilities of its ECOsynthesis platform without quality barriers, marking a significant advancement in biocatalytic enzyme innovation.
- Production Capacity Expansion: In 2026, Codexis has scaled production to 100 grams at its Eco Innovation Lab, with plans to reach half a kilo by year-end, further addressing customer demand for large-scale siRNA production.
- Strong Financial Performance: Codexis reported total revenues of $38.9 million for 2025, a significant increase from $21.5 million in 2024, primarily driven by a technology transfer agreement with Merck, with 2026 revenue expected to range between $72 million and $76 million.
See More
Codexis Reports Significant Growth in FY 2025 Performance
- Significant Revenue Growth: Codexis achieved total revenue of $70.4 million in FY 2025, a 19.1% increase from $59.3 million in FY 2024, indicating strong performance amid recovering market demand, which is expected to further boost investor confidence.
- Improved Gross Margin: The product gross margin for FY 2025 reached 64%, up from 56% in FY 2024, reflecting successful cost control and pricing strategies that enhance profitability and operational efficiency.
- R&D Spending Adjustments: Although R&D expenses increased to $52.3 million for FY 2025, Q4 spending was $11.7 million, down from $12.1 million in Q4 2024, demonstrating the company's flexible adjustments in R&D investment to respond to market dynamics.
- Strong Cash Position: By the end of 2025, Codexis reported $78.2 million in cash and short-term investments, bolstered by a $37.8 million technology transfer agreement with Merck, ensuring operational and capital expenditure needs for the next two years, thereby enhancing financial stability.
See More
Codexis Q4 2025 Earnings Call Highlights
- Significant Revenue Growth: Codexis reported total revenues of $38.9 million for Q4 2025, an 80% increase from $21.5 million in Q4 2024, primarily driven by a technology transfer agreement with Merck, indicating strong market demand in the RNA medicine sector.
- Technical Milestone Achieved: The company successfully synthesized 10 grams of commercially relevant siRNA, marking a significant technical advancement for the ECO Synthesis production platform, with plans to scale up to 0.5 kilograms by year-end, further solidifying its market position in chemoenzymatic production.
- Production Capacity Expansion: Codexis is set to complete the construction of a new GMP facility by the end of 2027, which is expected to significantly enhance its production capabilities to meet growing customer demands, bolstered by three CDMO agreements signed with Bachem, Nitto Avecia, and Axolabs.
- Improved Financial Position: Although the net loss for 2025 was $44 million, an improvement from a $65.3 million loss in 2024, the company achieved a net income of $9.6 million in Q4, reflecting a positive shift towards profitability and operational efficiency.
See More
Codexis (CDXS) Q4 2025 Earnings Call Transcript
See More
Codexis Q4 Earnings Exceed Expectations
- Strong Performance: Codexis reported a Q4 GAAP EPS of $0.11, beating expectations by $0.14, indicating a significant improvement in profitability and enhancing its competitive position in the market.
- Revenue Surge: The company achieved Q4 revenue of $38.9 million, representing an 81.3% year-over-year increase and exceeding market expectations by $3.07 million, highlighting Codexis's robust business expansion and demand.
- Positive Outlook: Total revenues are projected to range between $72 million and $76 million for 2026, providing investor confidence and indicating the company's potential for sustained growth in the coming years.
- Sufficient Funding: Codexis expects that its existing cash, cash equivalents, and short-term investments will be adequate to fund planned operations through the end of 2027, demonstrating sound financial management and sustainability.
See More
Codexis to Announce Q4 Earnings on March 11
- Earnings Announcement Schedule: Codexis is set to release its Q4 earnings on March 11 after market close, with market participants keenly awaiting the results, which are expected to influence stock performance.
- EPS Expectations: Analysts forecast an EPS of -$0.04, representing a 69.2% year-over-year improvement, indicating significant potential for enhanced profitability for the company.
- Revenue Growth Forecast: The revenue estimate stands at $35.83 million, reflecting a 67.0% year-over-year increase, showcasing strong market demand and sales growth that could bolster investor confidence.
- Historical Performance Insight: Historical financial data indicates that Codexis has shown gradual improvement over recent quarters, and if this earnings report meets expectations, it will further solidify its market position in the biotechnology sector.
See More
